Olanzapine for the Treatment of Refractory Chronic Nausea and Vomiting

NCT02977741 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2018-08-20

No results posted yet for this study

Summary

Prospective, observational study evaluating the effect of olanzapine for the treatment of refractory chronic nausea and vomiting.

Conditions

Interventions

DRUG

Olanzapine

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02977741 on ClinicalTrials.gov